CGX-1321

磷酸源生萘啶

Report date: 2022/10/23 12:51:12
NME

Base Information

Drug NameCGX-1321
Drug Alias Name源生萘啶CGX-1321
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein-serine O-palmitoleoyltransferase porcupine inhibitorsWnt signalling pathway inhibitors
TargetsProtein-serine O-palmitoleoyltransferase porcupine
Therapy Area/IndicationsSolid tumoursPancreatic NeoplasmsStomach Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGuangzhou Curegenix Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesGuangzhou Curegenix Inc
Inactive CompaniesCuregenix Inc
Active IndicationsGastrointestinal Neoplasms
Inactive IndicationsSolid tumoursPancreatic NeoplasmsStomach Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksN/A